Impressing Investors: How Regulatory Perks Can Power Rare Disease Research

 
• By Eliza Slawther
  
Dan Williams is CEO and co-founder of UK biotech SynaptixBio (SynaptixBio)

More from Interviews

More from Health Technology Assessment